benzyl-(2-chloro-ethyl)-ethyl-amine | 60154-59-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl-(2-chloro-ethyl)-ethyl-amine
• 英文别名: ethyl-benzyl-(2-chloro-ethyl)-amine；Aethyl-benzyl-(2-chlor-aethyl)-amin；2-(N-benzyl-N-ethylamino)ethyl chloride；2--aethylchlorid；Benzenemethanamine, N-(2-chloroethyl)-N-ethyl-；N-benzyl-2-chloro-N-ethylethanamine
• CAS: 60154-59-8
• 化学式: C₁₁H₁₆ClN
• 分子量: 197.708
• InChiKey: PEDYEFUCMXSQJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  8-氨基-6-甲氧基喹啉 、 benzyl-(2-chloro-ethyl)-ethyl-amine 在 乙醇 作用下， 生成 N-ethyl-N-benzyl-N'-(6-methoxy-[8]quinolyl)-ethylenediamine
  参考文献：
  名称：

  Derivatives of 6-Methoxy-8-aminoquinoline and 2-Methyl-6-methoxy-8-aminoquinoline. I

  摘要：

  DOI：

  10.1021/ja01238a009
• 作为产物：
  描述：

  2-[苄基(乙基)氨基]乙醇 在 甲基磺酰氯 作用下， 以 吡啶 为溶剂， 以63%的产率得到benzyl-(2-chloro-ethyl)-ethyl-amine
  参考文献：
  名称：

  Trace amine-associated receptor 1 (TAAR1) is activated by amiodarone metabolites

  摘要：

  Amiodarone (Cordarone, Wyeth-Ayerst Pharmaceuticals) is a clinically available drug used to treat a wide variety of cardiac arrhythmias. We report here the synthesis and characterization of a panel of potential amiodarone metabolites that have significant structural similarity to thyroid hormone and its metabolites the iodothyronamines. Several of these amiodarone derivatives act as specific agonists of the G protein-coupled receptor (GPCR) trace amine-associated receptor 1 (TAAR(1)). This result demonstrates a novel molecular target for amiodarone derivatives with potential clinical significance. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.013

文献信息

• [EN] QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE QUINOLÉINE ET DE QUINAZOLINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：STINGRAY THERAPEUTICS INC

  公开号：WO2020190912A1

  公开（公告）日：2020-09-24

  Compounds and methods for their preparation and use as therapeutic or prophylactic agents, fo example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1).

  化合物及其制备和用作治疗或预防剂的方法，例如通过靶向Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1)来治疗癌症、细菌或病毒性疾病。
• Non-peptidyl tachykinin receptor antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0694535A1

  公开（公告）日：1996-01-31

  This invention provides novel substituted benzimidazoles of formula II which are useful as tachykinin receptor antagonists. This invention also provides methods for treating a condition associated with an excess of tachykinin which comprises administering to a mammal in need thereof one of a series of substituted benzimidazoles. This invention further provides pharmaceutical formulations comprising one or more of the substituted benzimidazoles of the present invention in association with pharmaceutical carriers, diluents, or excipients. A and Ra-Re are as defined in the description.

  这项发明提供了一种新颖的公式II的取代苯并咪唑，它们可用作快速激肽受体拮抗剂。这项发明还提供了治疗与快速激肽过剩有关的疾病的方法，包括向需要的哺乳动物中给予一系列取代苯并咪唑中的一种。这项发明还提供了包含本发明中一种或多种取代苯并咪唑与药用载体、稀释剂或赋形剂相关联的药物配方。A和Ra-Re如描述中所定义。
• Isoquinolinylsulfonamides as anti-arrhythmic agents
  申请人：Pfizer Inc.

  公开号：US05114952A1

  公开（公告）日：1992-05-19

  A series of novel alkanesulphonamidophenyl-N-alkyl-N-(heterocyclic-alkyl)alkylamine derivatives have been prepared, including their pharmaceutically acceptable salts. These compounds are useful in therapy as anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Said sulfonamide compounds are of the formula: ##STR1## wherein R and R.sup.1 are each C.sub.1 -C.sub.4 alkyl; X is --CH.sub.2 --, --CO-- or --CH(OH)--; n is two, three or four; and "Het" is a nitrogen-containing heterocyclic group wherein said heterocyclic group is preferably 2H-3,4-dihydroisoquinol-1-on-2-yl or 2H-isoquinol-1-on-2-yl, each optionally substituted with halogen or C.sub.1 -C.sub.4 alkyl.

  一系列新型的烷基磺酰胺基苯基-N-烷基-N-(杂环烷基)烷基胺衍生物已被制备，包括它们的药学上可接受的盐。这些化合物在治疗抗心律失常药物方面非常有用，因此对于治疗各种心脏心律失常具有价值。所述磺酰胺化合物的化学式为：##STR1## 其中R和R.sup.1分别为C.sub.1-C.sub.4烷基；X为--CH.sub.2--，--CO--或--CH(OH)--；n为二、三或四；而"Het"是一种含氮杂环基团，其中该杂环基团最好是2H-3,4-二氢异喹啉-1-酮-2-基或2H-异喹啉-1-酮-2-基，每个基团可选择性地被卤素或C.sub.1-C.sub.4烷基取代。
• Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
  申请人：Ishikawa, Masayuki

  公开号：EP0040793A1

  公开（公告）日：1981-12-02

  A 5,6,7-substituted-2,4 (1H,3H)-quinazolinedione compound of the formula (I), wherein R1, R2, R3, A and B as defined in claim 1 and its acid addition salt; and a vasodilating and hypotensive composition containing the aforesaid compound.

  一种式（I）的 5，6，7-取代的-2，4（1H，3H）-喹唑啉二酮化合物、 其中 R1、R2、R3、A 和 B 如权利要求 1 所定义及其酸加成盐；以及含有上述化合物的血管扩张和降血压组合物。
• Alpha-(Aminoalkyl)-Arylacetic Acid Derivatives
  申请人：FISONS CORPORATION (a Massachusetts corporation)

  公开号：EP0222099A2

  公开（公告）日：1987-05-20

  Novel α-aryl-α-(ω-aminoalkyl)-α-[hydroxy(aralkyl and cycloalkyl)]acetic acid derivatives and α-aryl-α-(ω-aminoalkyl)-α[alkanoyloxy(aralkyl and cycloalkyl)]acetic acid derivatives, such as N,N-dimethyl-2-(hydroxyphenylmethyl)-4-dimethylamino­2-phenylbutanamide, 2-(hydroxyphenylmethyl)-5-dimethylamino-­2-phenylpentanenitrile, ethyl 2-(hydroxyphenylmethyl)-5-­dimethylamino-2-phenylpentanoate, and N,N-dimethyl-2[(acetyloxy)phenylmethyl]-4-dimethylamino-­2-phenylbutanamide, useful in the treatment of cardiovascular disease.

  新型α-芳基-α-(ω-氨基烷基)-α-[羟基(芳烷基和环烷基)]乙酸衍生物和α-芳基-α-(ω-氨基烷基)-α-[烷酰氧基(芳烷基和环烷基)]乙酸衍生物，如 N,N-二甲基-2-(羟基苯基甲基)-4-二甲基氨基-2-苯基丁酰胺、2-(羟基苯基甲基)-5-二甲氨基-2-苯基戊腈、2-(羟基苯基甲基)-5-二甲氨基-2-苯基戊酸乙酯和 N,N-二甲基-2[(乙酰氧基)苯基甲基]-4-二甲氨基-2-苯基丁酰胺，可用于治疗心血管疾病。